Townsend B L, Cohen P R, Duvic M
Department of Dermatology, University of Texas-Houston Medical School 77030, USA.
J Am Acad Dermatol. 1995 Jun;32(6):994-9. doi: 10.1016/0190-9622(95)91338-6.
Zidovudine, an inhibitor of HIV replication, has been reported to improve psoriasis in HIV-positive patients.
Our purpose was to evaluate the safety, tolerance, and effectiveness of oral zidovudine for treating psoriasis in HIV-negative patients in a small, open-label study.
Each subject received 200 mg of zidovudine every 4 hours during waking hours, for a total of 1000 mg/day. Treatment was continued for 8 weeks, at which time the patient's response to therapy was evaluated. If a response was evident, treatment was continued for an additional 8 weeks. Clinical response was correlated with histologic changes in skin lesions at 0 and 4 weeks.
Thirty-three percent of HIV-negative patients with psoriasis showed improvement by up to 80% after 16 weeks of therapy; decreased elevation and scaling of the psoriasis plaques were the most notable changes. No complete remissions occurred.
This is the first report of the use of zidovudine to treat HIV-negative patients with psoriasis. Although zidovudine was well tolerated, it may be more effective in HIV-positive patients with psoriasis.
齐多夫定是一种HIV复制抑制剂，据报道可改善HIV阳性患者的银屑病。
我们的目的是在一项小型开放标签研究中评估口服齐多夫定治疗HIV阴性患者银屑病的安全性、耐受性和有效性。
每位受试者在清醒时间每4小时服用200毫克齐多夫定，每日总量为1000毫克。治疗持续8周，届时评估患者对治疗的反应。如果有明显反应，则继续治疗8周。在第0周和第4周时，将临床反应与皮肤病变的组织学变化相关联。
接受治疗16周后，33%的HIV阴性银屑病患者病情改善达80%；银屑病斑块隆起和鳞屑减少是最显著的变化。无完全缓解情况发生。
这是使用齐多夫定治疗HIV阴性银屑病患者的首份报告。尽管齐多夫定耐受性良好，但它可能对HIV阳性银屑病患者更有效。
